Loading clinical trials...
Loading clinical trials...
The study will improve our understanding of the "prosocial" effects of ± 3,4-Methylenedioxymethamphetamine (MDMA), relative to a prototypical stimulant, methamphetamine (MA). The investigators seek to characterize the "uniquely social" effects of MDMA.
Age
18 - 35 years
Sex
ALL
Healthy Volunteers
Yes
University of Chicago
Chicago, Illinois, United States
Start Date
June 1, 2016
Primary Completion Date
August 1, 2018
Completion Date
August 1, 2018
Last Updated
January 5, 2024
36
ACTUAL participants
3,4-Methylenedioxymethamphetamine
DRUG
methamphetamine
DRUG
Lead Sponsor
University of Chicago
NCT07310264
NCT06290258
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions